ClinicalTrials.gg
Not yet recruitingNCT07443592LAL-2025Updated Mar 2, 2026

Treatment for Ph-negative ALL for Adults up to 65 Years

An interventional study of Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL) and Transplantation in Acute Lymphoblastic Leukemia, sponsored by PETHEMA Foundation. Not yet recruiting at 95 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by PETHEMA Foundation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation — 3 open to participants now, 3 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · PETHEMA Foundation.

Planned enrollment
2nd of 16
330 · median 100
Started
2026
the only one that year
No phase
3 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 19th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation, or all of them as a file.
02

Study summary

The goal of this trial is to provide a protocol for treatment for adults with Ph-negative acute lymphoblastic leukemia (ALL) and to learn if this provides higher probability of survival than the previous one. The main question is to know if the incorporation of blinatumomab for B-cell precursor ALL, substituting some chemotherapy blocks, offers better probability of survival than the previous trial, which did not use immunotherapy. In addition, T-cell precursor ALL participants will receive different treatment approaches depending on the stage of maturation of the tumor.

Read the detailed description

Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).

Resistant participants will receive a second induction with inotuzumab for B-cell precursor ALL or with FLAG-Ida (fludarabine, cytarabine, idarubicin and granulocyte colony stimulating factor) for T-cell precursor ALL.

B-cell precursor ALL participants with adequate MRD clearance after cycle 1 of blinatumomab will receive 3 blocks of early consolidation. If adequate MRD clearance and good genetic background, the patients will proceed to delayed intensification, reinduction and maintenance. The remaining patients will receive early or delayed alloHSCT.

T-cell precursor ALL participants with adequate MRD clearance after the first cycle of consolidation will receive 2 blocks of early consolidation and reinduction. If adequate MRD clearance and good genetic background, the patients will proceed to delayed intensification and maintenance. The remaining patients will receive early or delayed alloHSCT.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • ALL
  • adult
  • Philadephia-negative
  • minimal residual disease
  • genetics
  • immunotherapy
  • transplantation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • De novo ALL.
  • Age 18-65 years.
  • No prior treatment, except:

Urgent leukapheresis, Urgent treatment of hyperleukocytosis with hydroxyurea, Urgent cranial irradiation (one dose) for CNS leukostasis, Urgent mediastinal irradiation for superior vena cava syndrome.

  • Adequate general condition ( score 0-2), or >2 if due to ALL.
  • Negative pregnancy test for women of childbearing age.

Exclusion criteria

Exclusion Criteria:

  • Age > 65 years.
  • ALL type L3 or with mature B phenotype (sIg+) or with the cytogenetic alterations characteristic of mature B-cell ALL (t(8;14), t(2;8), t(8;22)).
  • Ph-positive B-cell ALL (BCR::ABL1).
  • Lymphoid blast crisis of chronic myeloid leukemia.
  • Patients with a history of coronary artery disease, valvular heart disease, or hypertensive heart disease, which contraindicates the use of anthracyclines.
  • Patients with active chronic liver disease.
  • Patients with severe chronic respiratory failure.
  • Renal insufficiency not due to ALL.
  • Severe neurological disorders, not due to ALL, that contraindicate the use of these treatments (especially blinatumomab).
  • History of pancreatitis, at the investigator's discretion (taking into account the date of the pancreatitis, its previous severity, and sequelae).
  • Pregnancy or breastfeeding.
  • Psychiatric or mental illness that prevents providing for sample submission or adequately participating in the study.
  • Impaired general health ( scores 3 and 4) not attributable to ALL.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Other
    Chemotherapy (+ blinatumomab for B-cell precursor ALL)

    Pediatric-inspired chemotherapy

    Drug: Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL)

  • Other
    Transplantation

    allogeneic stem cell transplantation

    Procedure: Transplantation

Interventions

  • DrugPediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL)

    Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine). Blinatumomab cycles in consolidation therapy for participants with B-cell precursor ALL.

  • ProcedureTransplantation

    allogeneic stem cell transplantation

06

What researchers measure

Primary outcomes

  1. Overall survival comparison versus previous trial

    Comparison of time from diagnosis to death or last follow-up between the present LAL-2025 trial and the previous LAL19 trial for adult Ph-negative

    Time frame: 5 years

Secondary outcomes

  1. Complete remission (CR) rate

    Proportion of participants who achieve CR with or 2 induction therapy lines

    Time frame: 4 or 8 weeks after treatment onset

  2. MRD status after induction and consolidation

    Proportion of participants who achieve and maintain the negative MRD status (\<10-4)

    Time frame: After induction (4-8 weeks) and consolidation (16-20 weeks)

  3. MRD variation between induction and after cycle 1 blinatumomab

    Proportion of B-cell precursor ALL participants who achieve and maintain the negative MRD status (\<10-4) at week 4 or 8 (end of induction 1 or 2) and after week 8 or 12 (after blinatumomab cycle1)

    Time frame: After induction (4-8 weeks) and after cycle 1 blinatumomab (8-12 weeks)

  4. Frequency of allogeneic stem cell transplantation (alloSCT) dut to high-risk genetics

    Proportion of participants that are allocated to alloSCT exclusively due to the presence to high-risk genetic alterations defined in the trial

    Time frame: 5 years

  5. Effect of blinatumomab within each B-cell precursor ALL genetic subtype

    Proportion of paarticipants with negative MRD status within each B-cell precursor ALL genetic subtype according to the World Health Organization (WHO) and the International Consensus Classification of Acute Leukemia (ICC)

    Time frame: 5 years

07

Study locations

95 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2031, 60 months later.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 60 months is above that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 2, 2026
StartEst.
Mar 6, 2026
Primary completionEst.
Mar 6, 2031
CompletionEst.
Jun 1, 2033
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443592
Lead sponsor
PETHEMA Foundation
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 6, 2026 (estimated)
Primary completion
Mar 6, 2031 (estimated)
Completion
Jun 1, 2033 (estimated)
Last update
Mar 2, 2026

Study contacts

Anna Torrent, Dr
Contact
atorrent@iconcologia.net
+34934978987
Josep Maria Ribera
Contact
jribera@iconcologia.net
+34934978987
Anna Torrent, Dr
study chair · Germans Trias i Pujol Hospital
Pere Barba, Dr
study chair · Hospital Vall d'Hebrón
Josep Maria Ribera, Prof
study chair · Germans Trias i Pujol Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion